Biogen shares are trading roughly flat today, showing mild consolidation after the stock reached a new 52-week high of $229.62 during the previous session.
The recent price action follows a period of investor focus on the company's shifting revenue mix, as its growth portfolio—led by products like Skyclarys and Zurzuvae—increasingly outpaces its legacy multiple sclerosis drugs. The stock's performance is also aligning with a broader downturn across the healthcare sector,